Skip to content
Menu

Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.

Read at benzinga.com